Download PDFPDF
Extended report
Clinical efficacy and safety of glucosamine, chondroitin sulphate, their combination, celecoxib or placebo taken to treat osteoarthritis of the knee: 2-year results from GAIT
Compose Response

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g.
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests


  • Responses are moderated before posting and publication is at the absolute discretion of BMJ, however they are not peer-reviewed
  • Once published, you will not have the right to remove or edit your response. Removal or editing of responses is at BMJ's absolute discretion
  • If patients could recognise themselves, or anyone else could recognise a patient from your description, please obtain the patient's written consent to publication and send them to the editorial office before submitting your response [Patient consent forms]
  • By submitting this response you are agreeing to our full [Response terms and requirements]

Vertical Tabs

Other responses

Jump to comment:

  • Published on:
    Long term knee OA trial design: an ounce of prevention is worth a pound of cure
    • Jean-Pierre Pelletier, Professor of Medicine
    • Other Contributors:
      • Johanne Martel-Pelletier, Lukas M. Wildi, and Jean-Pierre Raynauld

    Dear Editor,

    Sawitzke et al (1) reported on the results from the GAIT study assessing the long term effects of 2-year treatment on knee osteoarthritis (OA) symptoms. The findings indicate that the effects of glucosamine hydrochloride (GHCl), chondroitin sulfate (CS), and celecoxib treatment were not better than placebo, although safe and well tolerated.
    The study results are not surprising in view of the original G...

    Show More
    Conflict of Interest:
    None declared.